HEME Patient Marketing Associate Director at Vertex Pharmaceuticals | Boston, MA | $163K/yr – $244K/yr

Vertex Pharmaceuticals

HEME Patient Marketing Associate Director

Boston, MA (Hybrid)

$163K/yr – $244K/yrSenior Level7+ years expFull time

Posted 1 month ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own patient marketing initiatives with a strong regulatory spine, ensuring patient and provider insights shape compliant campaigns while coordinating across HCP marketing, sales, PSP, and Market Research to drive execution.

CRC champion for patient core materials, guaranteeing regulatory-compliant marketing across assets and channels.
Lead cross-functional collaboration to translate patient insights into campaigns with tight alignment to timelines and budgets.
Oversight of external agencies and vendors to deliver high-quality patient-focused programs on schedule.

Job Description

Responsibilities

Partner with patient advocacy groups, healthcare providers, and other stakeholders to understand patient needs and incorporate their perspectives into marketing strategies.
Demonstrate effective collaboration with stakeholder teams, including HCP marketing, sales, PSP, and Market Research to ensure seamless execution of patient marketing initiatives.
Stay updated on industry trends and best practices in consumer marketing, consumer engagement, and regulatory compliance, infusing learnings as appropriate.
Serve as the CRC champion for all patient core material development ensuring all patient marketing activities comply with regulatory and compliance standards.
Manage external agencies and vendors to ensure high-quality deliverables and adherence to timelines and budgets.

Requirements

Bachelor’s degree in Marketing, Business, Life Sciences, or a related field
7+ years of experience in pharmaceutical, biotechnology, or healthcare marketing, with a focus on patient marketing

Preferred

MBA or advanced degree preferred
knowledge of regulatory and compliance standards in the pharmaceutical industry (nice to have)

Benefits

From medical, dental and vision benefits to generous paid time off (including a week-long company shutdown in the Summer and the Winter)
educational assistance programs including student loan repayment
a generous commuting subsidy
matching charitable donations
401(k) and so much more

Vertex Pharmaceuticals

4.2 Glassdoor

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and has made significant advancements in multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain — and continues to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Our global headquarters is in Boston, and we have research and development (R&D) sites and commercial offices worldwide.Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards.Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/

Founded in 1989

Boston, Massachusetts, USA

6.1K employees (282 in marketing)

www.vrtx.com

83% recommend to a friend

88% CEO approval